Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.

[1]  V. Conteduca,et al.  Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. , 2021, European urology oncology.

[2]  V. Conteduca,et al.  New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer , 2021, Cells.

[3]  H. Scher,et al.  Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. , 2020, European urology.

[4]  A. Wyatt,et al.  Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. , 2019, JCO precision oncology.

[5]  E. Scarpi,et al.  Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. , 2019, European journal of cancer.

[6]  E. Scarpi,et al.  Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. , 2019, JCO precision oncology.

[7]  A. Zoubeidi,et al.  Biological Evolution of Castration-resistant Prostate Cancer. , 2019, European urology focus.

[8]  E. Scarpi,et al.  Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer , 2019, European urology.

[9]  E. Gallardo,et al.  PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Wyatt,et al.  Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA). , 2018 .

[11]  D. Amadori,et al.  Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Matti Nykter,et al.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[13]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Scarpi,et al.  Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer , 2016, Oncotarget.

[15]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[16]  Delila Gasi Tandefelt,et al.  Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.

[17]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[18]  E. Wiemer,et al.  Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. , 2015, European urology.

[19]  D. Amadori,et al.  Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.

[20]  E. Wiemer,et al.  Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.

[21]  H. Joensuu,et al.  2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[22]  H. Joensuu,et al.  Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. , 2012, Anticancer research.

[23]  N. Bander,et al.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. , 2011, Cancer research.

[24]  D. Qian,et al.  Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. , 2010, Cancer research.

[25]  Yuzhuo Wang,et al.  Experimental Therapeutics , Molecular Targets , and Chemical Biology Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer , 2009 .

[26]  S. Fosså,et al.  Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. , 2007, European urology.

[27]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[28]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[29]  T. Beer,et al.  Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged ≥ 70 Years Compared with Patients Aged < 70 Years , 2003 .